¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"site specific mutation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® mutation ÇÑ±Û µ¹¿¬º¯ÀÌ
¼³¸í   
  ¼¼Æ÷ÀÇ dna ÀÚüÀÇ º¯ÀÌ¿¡ ÀÇÇØ ÀϾ´Â ¼¼Æ÷º¯À̸¦ ¸»ÇÑ´Ù. ÀÌ·¯ÇÑ °æ¿ì µ¹¿¬º¯À̷ΠÀϾ ¼¼Æ÷´Â ±× ÀÌÈÄ µþ¼¼Æ÷(daughter cell)¿¡¼­µµ ±× º¯À̰¡ ¿©ÀüÈ÷ À¯ÁöµÇ¹Ç·Î Á¾(species)ÀÇ º¯È­³ª, È¤Àº ¼¼Æ÷ÀÇ ¾Ç¼ºº¯È¯(malignant transformation)¿¡ °ü¿©ÇÑ´Ù.
¿µ¹® specific gravity ÇÑ±Û ºñÁß
¼³¸í   
  ´ÜÀ§ ºÎÇÇ´ç Áú·®. ¼Òº¯ÀÇ ºñÁßÀº ¼Òº¯ÀÇ ³óµµ¸¦ ¹Ý¿µÇÑ´Ù. ¿¹¸¦ µé¾î ¼Òº¯ÀÇ ºñÁßÀÌ Å©¸é, ÄáÆÏÀÇ ¹°Èí¼ö°¡ ¿øÈ°È÷ ÀÌ·ç¾îÁö°í ÀÖÀ½À» ³ªÅ¸³½´Ù.
  
  
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • donor site
    Á¦°øºÎÀ§, °ø¿©ºÎÀ§
  • fragile site
    Ãë¾àºÎÀ§
  • ligand binding site
    ¸®°£µå°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • site
    ºÎÀ§
  • telomeric site
    ³¡ºÐÀýºÎÀ§
  • allelic mutation
    ¸Â¼¶µ¹¿¬º¯ÀÌ, ´ë¸³µ¹¿¬º¯ÀÌ
  • back mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • site
    ºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • platelet-specific antigen
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • specific activity
    ºñ¹æ»ç´É, ƯÀÌȰ¼ºµµ
  • specific gravity
    ºñÁß
  • mutation
    µ¹¿¬º¯ÀÌ
  • point mutation
    Á¡µ¹¿¬º¯ÀÌ
  • reverse mutation
    ¿ªµ¹¿¬º¯ÀÌ, º¹±Íµ¹¿¬º¯ÀÌ
  • somatic mutation
    ü¼¼Æ÷µ¹¿¬º¯ÀÌ
  • specific phobia
    ƯÁ¤°øÆ÷(Áõ)
  • mutation rate
    µ¹¿¬º¯ÀÌÀ²
  • specific
    ƯÀÌ-, ƯÁ¤-
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption site
    Èí¼öºÎÀ§
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ººÎÀ§
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • binding site
    °áÇÕºÎÀ§
  • combining site
    °áÇÕºÎÀ§
  • definitive site
    Âø»óºÎÀ§
  • donor site
    ÁִºÎÀ§, Á¦°øºÎÀ§
  • mutational site
    µ¹¿¬º¯À̺ÎÀ§
  • packaging site
    ²Ù¸®±âºÎÀ§
  • privileged site
    Ưº°°Ý¸®ºÎÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • frameshift mutation
    ÇØµ¶Æ² µ¹¿¬º¯ÀÌ, ÇÁ·¹ÀÓ½¬ÇÁÆ® µ¹¿¬º¯ÀÌ
  • fundic site
    ÀڱùٴÚÀÓ½Å
  • genetic mutation
    À¯ÀüÀû µ¹¿¬º¯ÀÌ
  • genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ßµ¹¿¬º¯ÀÌ
  • induced mutation
    À¯¹ß¼º µ¹¿¬º¯ÀÌ.
  • placental site trophoblastic tumor
    ŹݺÎÂøºÎÀ§ À¶¸ð»óÇǼºÁ¾¾ç
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • absorption site
    Èí¼öÁ¡
  • acceptor site
    ¼ö¿ëºÎÀ§
  • active site
    Ȱ¼ºÀÚ¸®.
  • antibody binding site
    Ç×ü°áÇÕºÎÀ§
  • antibody combining site
    Ç×ü°áÇÕºÎ(ù÷ô÷Ì¿ùêÝ»).
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
  • antigen recognition site
    Ç׿ø½Äº°ºÎ.
  • binding site
    °áÇÕºÎÀ§.
  • binding site
    °á ÇÕºÎÀ§.
  • combining site
    °áÇÕºÎ(Ì¿ùêÝ»).
  • combining site
    °áÇÕºÎÀ§
  • combining site of antibody
    Ç×üÀÇ °áÇÕºÎ.
  • corporal site
    ÀڱøöÅëÀÓ½Å
  • definitive site
    Âø»óÀÚ¸®
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Genomic mutation
    À¯ÀüÀÚµ¹¿¬º¯ÀÌ
    [¿¾ ¿ë¾î] À¯ÀüÀÚµ¹¿¬º¯ÀÌ
  • Variations of site
    À§Ä¡º¯ÀÌ
    [¿¾ ¿ë¾î] À§Ä¡ÀÌ»ó
  • Corporal site
    ÀڱøöÅëÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃüºÎ
  • Absorption site
    Èí¼öÁ¡
    [¿¾ ¿ë¾î] Èí¼öÃÊÁ¡
  • Fundic site
    ÀڱùٴÚÀÓ½Å
    [¿¾ ¿ë¾î] ÀÚ±ÃÀúºÎ
  • Definitive site
    Âø»óÀÚ¸®
    [¿¾ ¿ë¾î] À§Ä¡¼±Á¤
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specific parasite
    ƯÀ̱â»ýÃæ
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • site-specific endonuclease
    ÀÚ¸® ƯÀ̼º(÷åì¶àõ) ¿£µµ´©Å¬¸®¿¡À̽º
  • site-specific inversion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ¿ªÀ§(æ½êÈ)
  • site-specific recombinstion
    ÀÚ¸®Æ¯ÀÌ(÷åì¶) ÀçÁ¶ÇÕ(î¢ðÚùê)
  • A-site-P-site moel
    AÀÚ¸® PÀÚ¸® ¸ðµ¨
  • second-site mutation
    µÑ° ÀÚ¸® º¯ÀÌ(ܨì¶)
  • single-site mutation
    ¿ÜÀÚ¸® º¯ÀÌ(ܨì¶)
  • apparent specific volume
    ¿Ü°ß(èâ̸) ºñ(Ýï)¿ëÀû(é»îÝ)
  • enzyme-specific electrode
    È¿¼ÒƯÀÌ Àü±Ø (ý£áÈ÷åì¶ï³Ð¿)
  • organ specific enzyme
    ±â°üƯÀÌÈ¿¼Ò(Ðïί÷åì¶ý£áÈ)
  • partial specific quantity
    Æíºñ·®(ø¶ÝïÕá)
  • partial specific volume
    Æíºñ¿ëÀû(ø¶Ýïé»îÝ)
  • plasma-specific enzyme
    Ç÷À寝ÀÌ È¿¼Ò(úìíì÷åì¶ý£áÈ)
  • relative specific activity
    »ó´ë ƯÀÌ È°¼ºµµ(ßÓÓß÷åì¶üÀàõÓø)
  • specific acid-base catalysis
    ƯÀÌ »ê.¿°±â Ã˸Å(÷åì¶ß«ç¤ÐñõºØÚ)
  • specific activity
    ºñȰ¼º(ÝïüÀàõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • mutation
    µ¹¿¬ º¯ÀÌ
  • site
    À§Ä¡,»çÀÌÆ®
  • specific absorption rate [=SAR]
    ƯÀÌÈí¼öÀ²
  • specific inflammation
    ƯÀ̼º¿°Áõ
  • web site
    À¥½ÎÀÌÆ®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
FS factor of safety; Fanconi syndrome; Felty syndrome; fibromyalgia syndrome; field stimulation; Fisher...
ARMS adverse reaction monitoring system; amplification refractory mutation system
MF magnetic field; meat free; medium frequency; megafarad; membrane filler; merthiolate-formaldehyde [s...
TFM testicular feminization male; testicular feminization mutation; total fluid movement; transmission e...
HSSCC hereditary site-specific colon cancer
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
RSM Restriction Site Mutation
Site 1 site
ARMS Amplification Refractory Mutation System
MFD Mutation frequency decline
RIP Repeat Induced Point mutation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific opiate receptor site
    Ưº°ÇÑ ¾ÆÆí ¼ö¿ëºÎ
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • cleavage site
    ºÐ¿­ ºÎÀ§
  • combining site
    °áÇÕºÎ
  • electrophilic site
    Ä£ÀüÀÚ ¹ÝÀÀ¹°
  • molecular site
    ºÐÀÚ À§
  • receptor site
    ¼ö¿ëü ºÎÀ§, ¼ö¿ëºÎ
    ƯÁ¤ÇÑ »ý¹°ÇÐÀû ¹ÝÀÀÀ» ÃÊ·¡ÇÏ´Â ºÐÀÚ °áÇÕÀÌ ÀϾ´Â ƯÁ¤ ºÎÀ§.
  • recognition site
    ÀÎ½Ä ºÎÀ§
  • site
    À§Ä¡, »çÀÌÆ®
  • site of pain modulation
    µ¿Åë Á¶Àý ºÎÀ§
  • surgical site
    ¼ö¼ú ºÎÀ§
  • web site
    À¥½ÎÀÌÆ®
    ÀÎÅͳݿ¡¼­ ¾î¶² Á¤º¸¸¦ Á¦°øÇϰí ÀÖ´Â ÇϳªÀÇ »çÀ̹ö °ø°£. ÀÎÅÍ³Ý ÁÖ¼Ò°¡ °¡¸®Å°´Â °÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
site-specific DNA-methyltransferase (adenine-specific) <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on adenine residues in a specific short base sequence in the host cell DNA. The enzyme catalyses the methylation of DNA adenine in the presence of s-adenosyl-l-methionine to form DNA containing 6-methylaminopurine and s-adenosyl-l-homocysteine.
Registry number: EC 2.1.1.72
(12 Dec 1998)
site-specific DNA methyltransferase (cytosine-specific) <enzyme> An enzyme responsible for producing a species-characteristic methylation pattern on cytosine residues in a specific short base sequence in the host cell's DNA. The enzyme catalyses the methylation of DNA cytosine in the presence of s-adenosyl-l-methionine to form s-adenosyl-l-homocysteine and DNA containing 5-methylcytosine.
Registry number: EC 2.1.1.73
(12 Dec 1998)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
deoxyribonucleases, type III site-specific <enzyme> Enzyme systems composed of two subunits and requiring ATP and magnesium for endonucleolytic activity; they do not function as atpases. They exist as complexes with modification methylases of similar specificity.
The systems recognise specific short DNA sequences and cleave a short distance, about 24 to 27 bases, away from the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.5
(12 Dec 1998)
deoxyribonucleases, type II site-specific <enzyme> Enzyme systems containing a single subunit and requiring only magnesium for endonucleolytic activity. The corresponding modification methylases are separate enzymes. The systems recognise specific short DNA sequences and cleave either within, or at a short specific distance from, the recognition sequence to give specific double-stranded fragments with terminal 5'-phosphates. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.4
(12 Dec 1998)
deoxyribonucleases, type I site-specific <enzyme> Enzyme systems containing three different subunits and requiring ATP, s-adenosylmethionine, and magnesium for endonucleolytic activity to give random double-stranded fragments with terminal 5'-phosphates. They function also as DNA-dependent atpases and modification methylases, catalyzing the reactions of EC 2.1.1.72 and EC 2.1.1.73 with similar site-specificity. The systems recognise specific short DNA sequences and cleave at sites remote from the recognition sequence. Enzymes from different microorganisms with the same specificity are called isoschizomers.
Registry number: EC 3.1.21.3
(12 Dec 1998)
acquired mutation A change in a gene or chromosome that occurs in a single cell after the conception of the individual. That change is then passed along to all cells descended from that cell. Acquired mutations are involved in the development of cancer.
(12 Dec 1998)
addition-deletion mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
addition mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
amber mutation <molecular biology> A mutation from a codon which codes for an amino acid into the amber codon UAG, which normally signals that the translation of mRNA into an amino acid chain should stop.
The mutation causes the amino acid chain to stop forming before it is actually completed.
(09 Oct 1997)
back mutation <molecular biology> A mutation that causes a mutant gene to revert to its original wild-type base sequence.
Compare: forward mutation.
(09 Oct 1997)
reading-frameshift mutation <molecular biology> A type of mutation that results from insertion or deletion of a single nucleotide into, or from, an open reading frame in the normal DNA sequence.
Normally, the genetic code is read in the wrong frame, three nucleotides at a time, and the entire sequence downstream of the mutation, is translated into a polypeptide with a garbled amino acid sequence from the mutated codon onwards. These mutations may be induced by certain types of mutagens or may occur spontaneously and usually result in the generation, downstream, of nonsense, chain termination codons.
Synonym: addition mutation, addition-deletion mutation, deletion mutation, reading-frameshift mutation.
(21 Jun 2000)
germinal mutation A mutation in the germ cells (the cells which will undergo meiosis to form the gametes). Such mutations are therefore passed on to offspring.
(09 Oct 1997)
germ-line mutation Any detectable and heritable alteration in the lineage of germ cells. Mutations in these cells (i.e., "generative" cells ancestral to the gametes) are transmitted to progeny while those in somatic cells are not.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specific
    ƯÁ¤ÇÑ,Ưº°ÇÑ
  • specific
    Ư¼öÇÑ;µ¶Æ¯ÇÑ;¸íÈ®ÇÑ;Á¾ÀÇ;Ưȿ ÀÖ´Â
  • specific duty
    Á¾·®¼¼
  • specific gravity
    ºñÁß
  • specific heat
    ºñ¿­
  • mutation
    º¯°æ
  • forward mutation
    ÀüÁø µ¹¿¬ º¯ÀÌ
  • frameshift mutation
    ÇÁ·¹ÀÓ½ÃÇÁÆ® µ¹¿¬ º¯ÀÌ
  • missense mutation
    ¹Ì½º¼¾½º µ¹¿¬ º¯ÀÌ
  • mutation
    º¯È­;µ¹¿¬ º¯ÀÌ;º¯Á¾;¸ðÀ½ º¯È­
  • neutral mutation
    Á߸³µ¹¿¬º¯ÀÌ
  • vowel mutation
    =UMLAUT
  • site
    À§Ä¡
  • caravan park (site)
    À̵¿ÁÖÅÃ(Æ®·¹ÀÏ·¯) ÁÖÂ÷Àå
  • ceru(s)site
    ¹é¿¬±¤
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á